1. Scrip
  2. >>Conferences
  3. >>ASCO

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

 
• By Alaric DeArment

The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.

L-R: Chirfi Guindo, chief marketing officer, human health; Marjorie Green, head of late-stage oncology development; Gregory Lubiniecki, VP late oncology development; Eliav Barr, chief medical officer, Merck Research Laboratories; Dean Li, president, Merck Research Laboratories • Source: Alaric DeArment

Fresh off a raft of data presentations at the American Society of Clinical Oncology’s 2023 meeting, Merck & Co., Inc. laid out an oncology product development strategy in which immuno-oncology and antibody-drug conjugates (ADC) will play a leading role, along with small-molecule drugs.

Executives from the company assembled for a 5 June investor event in Chicago to lay out how the company plans to remain competitive in an oncology field that has become...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

More from Conferences

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.